Summary of COVID-19 pemivibart studies

1. Wolfe et al., Safety and Efficacy of Pemivibart, a Long-Acting Monoclonal Antibody, for Prevention of Symptomatic COVID-19: Interim Results From the CANOPY Clinical Trial

477 patient pemivibart prophylaxis RCT: 75% lower hospitalization (p=0.34), 74% lower progression (p<0.0001), and 76% fewer symptomatic cases (p<0.0001).
Phase 3 trial of 306 immunocompromised adults and 484 non-immunocompromised adults showing pre-exposure prophylaxis with pemivibart was generally well-tolerated and provided protection against symptomatic COVID-19 through 6 months in immunocompromised individuals and 12 months in non-immunocompromised individuals.
Nov 2024, medRxiv, https://www.medrxiv.org/content/10.1101/2024.11.11.24317127, https://c19p.org/wolfe

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0